TY - JOUR
T1 - A novel neuroprotective mechanism of riluzole
T2 - Direct inhibition of protein kinase C
AU - Noh, Kyung Min
AU - Hwang, Jee Yeon
AU - Shin, Hyung Cheul
AU - Koh, Jae Young
N1 - Funding Information:
This study was supported by Creative Research Initiatives of the Korean Ministry of Science and Technology, The Asan Foundation (J.Y.K.), and the Hallym Academy of Sciences, Hallym University (J.Y.K. and H.C.S.).
PY - 2000
Y1 - 2000
N2 - In addition to its antiexcitotoxic action, the anti-amyotrophic lateral sclerosis (ALS) neuroprotectant riluzole protects against nonexcitotoxic oxidative neuronal injury. In light of evidence that protein kinase C (PKC) mediates oxidative stress in cortical culture, we examined the possibility that riluzole's antioxidative neuroprotection involves PKC inhibition. Riluzole (30 μM) blocked phorbol 12-myristate 13-acetate (PMA)-induced increases in membrane PKC activity in cultured cortical cells. Suggesting a direct action, riluzole also inhibited the activity of purified PKC. Consistently, both PKC depletion and oxidative neuronal death induced by PMA were markedly attenuated by riluzole. The site of action of riluzole on PKC was not likely the diacylglycerol binding site but the catalytic domain, since riluzole did not alter radiolabeled phorbol-12,13-dibutyrate binding, but inhibited PKM, the catalytic domain of PKC. However, increasing ATP concentrations did not alter the inhibition of PKC by riluzole, making it unlikely that riluzole is a competitive inhibitor of ATP binding at PKM. Present results have demonstrated that riluzole directly inhibits PKC, which action may contribute to its antioxidative neuroprotective effects. In addition, it appears possible that PKC inhibition may be able to explain some of its well-known channel inhibitory and neuroprotective effects. Combined with findings that PKC activity is increased in ALS, the present results suggest that PKC may be a potential therapeutic target in ALS. (C) 2000 Academic Press.
AB - In addition to its antiexcitotoxic action, the anti-amyotrophic lateral sclerosis (ALS) neuroprotectant riluzole protects against nonexcitotoxic oxidative neuronal injury. In light of evidence that protein kinase C (PKC) mediates oxidative stress in cortical culture, we examined the possibility that riluzole's antioxidative neuroprotection involves PKC inhibition. Riluzole (30 μM) blocked phorbol 12-myristate 13-acetate (PMA)-induced increases in membrane PKC activity in cultured cortical cells. Suggesting a direct action, riluzole also inhibited the activity of purified PKC. Consistently, both PKC depletion and oxidative neuronal death induced by PMA were markedly attenuated by riluzole. The site of action of riluzole on PKC was not likely the diacylglycerol binding site but the catalytic domain, since riluzole did not alter radiolabeled phorbol-12,13-dibutyrate binding, but inhibited PKM, the catalytic domain of PKC. However, increasing ATP concentrations did not alter the inhibition of PKC by riluzole, making it unlikely that riluzole is a competitive inhibitor of ATP binding at PKM. Present results have demonstrated that riluzole directly inhibits PKC, which action may contribute to its antioxidative neuroprotective effects. In addition, it appears possible that PKC inhibition may be able to explain some of its well-known channel inhibitory and neuroprotective effects. Combined with findings that PKC activity is increased in ALS, the present results suggest that PKC may be a potential therapeutic target in ALS. (C) 2000 Academic Press.
UR - http://www.scopus.com/inward/record.url?scp=0033830726&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033830726&partnerID=8YFLogxK
U2 - 10.1006/nbdi.2000.0297
DO - 10.1006/nbdi.2000.0297
M3 - Article
C2 - 10964608
AN - SCOPUS:0033830726
SN - 0969-9961
VL - 7
SP - 375
EP - 383
JO - Neurobiology of Disease
JF - Neurobiology of Disease
IS - 4
ER -